Brand Reference: Retin-A, Altreno, Renova
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tretinoin (All-Trans Retinoic Acid Cream/Gel) RxNorm Concept ID | 10753 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $112.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $24.50 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $28.00 / mo | 59 Zero-PHI Verified Patient Logs |
Directly binds nuclear RAR-alpha, RAR-beta, and RAR-gamma transcription complexes without metabolic conversion, normalizing follicular keratinocyte desquamation, blocking UV-induced AP-1 matrix metalloproteinases (MMP-1/MMP-9), and stimulating papillary dermal Type I/III procollagen synthesis.
Out-of-pocket price dispersion on Tretinoin (All-Trans Retinoic Acid Cream/Gel) spans $24.50 to $112.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.9200/unit, allowing cash buyers bypassing PBM spread pricing to retain $87.50 each month (78% reduction).
With Local epidermal turnover cycle (28 days) residence kinetics and 1%–2% percutaneous systemic absorption (negligible endogenous plasma shift) bioavailability, Tretinoin (All-Trans Retinoic Acid Cream/Gel) undergoes cutaneous cyp26a1/b1 4-hydroxylation and establishes therapeutic activity over 4–8 weeks comedolysis; 16–24 weeks dermal collagen remodeling.
Standard adult regimens span 0.025% pea-sized nocturnal application, 0.05% cream/lotion QHS, 0.1% gel/microsphere QHS. Prescribers screen specifically against pregnancy (avoid retinoids per teratogenic precaution); sunburned or eczematous barrier-compromised skin, while community micro-logs most frequently note retinization peeling (weeks 2–4) (44% of reports), uv photosensitivity (31% of reports), perioral dryness (26% of reports).
Across 59 verified cash-pay logs, Tretinoin (All-Trans Retinoic Acid Cream/Gel) achieves a 94.80% Worth-It rating with out-of-pocket spend averaging $28.00/mo versus $112.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.025% pea-sized nocturnal application for Tretinoin (All-Trans Retinoic Acid Cream/Gel); monthly out-of-pocket dropped to $21.56 compared with $112.00 retail.
Completed 10 weeks on Tretinoin (All-Trans Retinoic Acid Cream/Gel) (0.05% cream/lotion QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.1% gel/microsphere QHS Tretinoin (All-Trans Retinoic Acid Cream/Gel) sourced via Local Pharmacy ($28.42/mo cash pay without insurance prior authorization).